CJC 1295 with DAC
Long-acting CJC 1295 variant with a drug-affinity complex extending half-life to ~8 days.
How it works
Same GHRH-receptor agonism as the non-DAC version, but DAC bonds to circulating albumin, producing a sustained 'GH bleed' rather than discrete pulses.
Reported benefits
- Twice-weekly dosing convenience
- Sustained elevation of IGF-1
Dosage & administration
Research range: 1-2 mg subcutaneously 1-2x per week.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
CJC-1295, a long-acting GHRH analogue
Journal of Clinical Endocrinology & Metabolism · 2006
Sustained increase in mean GH and IGF-1 levels over 28 days.
Safety & warnings
- Sustained GH elevation may impair insulin sensitivity
- Avoid in active malignancy
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
2 mg
CD2
Box of 10 · $216
Single vial · $432
5 mg
CD5
Box of 10 · $516
Single vial · $1,032
Related guides
BPC 157
A pentadecapeptide derived from human gastric juice with broad regenerative effects in pre-clinical models.
TB500 (Thymosin B4 Acetate)
A synthetic fragment of thymosin β-4 that promotes cell migration, angiogenesis, and tissue repair.
BPC + TB Blend
Combined BPC 157 and TB500 blend used in recovery protocols to overlap angiogenic and cytoskeletal effects.